Nicolas Martin

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo et al. · The Lancet Respiratory Medicine · 2017 · 264 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Khalil Saleh, Amaury Daste, Nicolas Martin et al. · European Journal of Cancer · 2019 · 183 citations

Medicine, Oncology, Chemotherapy +10

Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial

Olivier Sitbon, Jaime Bosch, Emmanuelle Cottreel et al. · The Lancet Respiratory Medicine · 2019 · 182 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Kelly Chin, Olivier Sitbon, Martin Doelberg et al. · Journal of the American College of Cardiology · 2021 · 167 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study

David Chardin, M. Paquet, Renaud Schiappa et al. · Journal for ImmunoTherapy of Cancer · 2020 · 84 citations · Full text

Medicine, Oncology, Pharmacology +16